Karyopharm Therapeutics (KPTI) risk factors, FY2024 10-K

Risks Related to Commercialization and Product Development

1. 01adverse publicity about our products or favorable publicity about competitive products; and
2. 02our ability to maintain compliance with existing and new health care laws and regulations, including government pricing, price reporting and other disclosure requirements related to such laws and regulations, and the potential impact of such laws and regulations on physician prescribing practices and payor coverage
3. 03We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do
4. 04If we are not able to compete effectively against current or potential competitors, our business will not grow and our financial condition and operations will suffer
5. 05negative impacts resulting from a pandemic or other public health emergency, including impacts to healthcare systems and our trial sites’ ability to conduct trial
6. 06have the product removed from the market after obtaining marketing approval
7. 07our reputation may suffer
8. 08The results of previous clinical trials may not be predictive of future trial results, and interim or top-line data may be subject to change or qualification based on the complete analyses of data and, therefore, may not be predictive of the final results of a trial
9. 09We may not be successful in our efforts to identify or discover additional potential product candidates, or our decisions to prioritize the development of certain product candidates over others may later prove wrong
10. 10potential product candidates may not be effective in treating their targeted diseases
11. 11If we are unable to maintain or expand our sales, marketing and distribution capabilities, we may not be successful in commercializing XPOVIO or any of our products or product candidates, if approved, that we may acquire or develop
12. 12our ability to supply sufficient inventory of our products for commercial sale
13. 13Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of XPOVIO or any other products that we may develop or acquire
14. 14the inability to successfully commercialize XPOVIO and any other products that we may develop or acquire
15. 15The business that we or our collaborators conduct outside of the U.S. may be adversely affected by international risks and uncertainties

Risks Related to Regulatory Matters

1. 16a product may not be approved for the indications that we, or our collaborators, request or may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable
2. 17injunctions or the imposition of civil or criminal penalties
3. 18We, or our collaborators, may not be able to obtain orphan drug exclusivity for any product candidates we, or they, may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products
4. 19Current and future legislation may increase the difficulty and cost for us, or any collaborators, to obtain marketing approval and commercialize our or their product candidates, if approved, and affect the prices we, or they, may obtain
5. 20The prices of prescription pharmaceuticals in the U.S. and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed
6. 21Our reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental drug pricing programs are complex and may involve subjective decisions. Any failure to comply with those obligations could subject us to penalties and sanctions
7. 22Our employees, independent contractors, consultants, collaborators and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and/or requirements and insider trading, which could cause significant liability for us and harm our reputation
8. 23If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business
9. 24Laws and regulations governing international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the U.S. and require us to develop and implement costly compliance programs
10. 25With the passage of the CREATES Act, we are exposed to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications
11. 26We are subject to governmental export and import controls that could impair our or our collaborators’ ability to compete in international markets due to licensing requirements and subject us or them to liability if we or they are not in compliance with applicable laws
12. 27Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results

Risks Related to Our Financial Position and Capital Requirements

1. 28Our financial condition raises substantial doubt as to our ability to continue as a going concern
2. 29We have incurred significant losses since inception, expect to continue to incur significant losses, and may never achieve or maintain profitability
3. 30navigating the negative impacts to healthcare systems, the ability of our clinical trial sites to conduct current or future trials and the regulatory review process as the result of pandemics or other public health emergencies
4. 31acquire or in-license other products, product candidates or technologies
5. 32We will need additional funding to achieve our business objectives. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate our research and development programs and/or commercialization efforts
6. 33our ability to continue as a going concern
7. 34Our indebtedness could limit cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under the Term Loan, the 2029 Notes, the 2025 Notes or the Amended Revenue Interest Agreement
8. 35placing us at a possible competitive disadvantage with competitors that are less leveraged than we are or have better access to capital
9. 36The conditional conversion feature of the 2025 Notes, if triggered, may adversely affect our financial condition and operating results
10. 37The accounting method for convertible debt securities such as the 2025 Notes and the 2029 Notes could have a material effect on our reported financial results
11. 38Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates
12. 39convertible debt and cannot enter into any new debt without the consent of HCRx, the required lenders or the required holders, respectively, subject to the exceptions and other provisions under the applicable governing document
13. 40Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price

Risks Related to Our Dependence on Third Parties

1. 41If we are unable to establish and maintain our agreements with third parties to distribute XPOVIO to patients, our results of operations and business could be adversely affected
2. 42We rely on third parties as we conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including not meeting local regulatory submission requirements or failing to meet deadlines for the completion of such trials, research or testing
3. 43We do not own or operate, and currently have no plans to establish, any manufacturing facilities for our products or product candidates. We currently rely, and expect to continue to rely, on third-party contract manufacturers to manufacture our products and product candidates for our commercial and clinical use
4. 44the possible misappropriation or disclosure by the third party or others of our proprietary information, including our trade secrets and know-how

Risks Related to Our Intellectual Property

1. 45We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful
2. 46Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
3. 47We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
4. 48Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
5. 49Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 50If our product candidates or any of our future product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such products, which may result in a material decline in sales of our competing products
7. 51If we do not successfully extend the term of patents covering our product candidates under the Hatch-Waxman Amendments and similar foreign legislation, our business may be materially harmed
8. 52If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
9. 53Not all of our trademarks are registered. Failure to secure those registrations could adversely affect our business

Risks Related to Our Operations and Employee Matters

1. 54Our future success depends on our ability to retain key members of our management team and to attract, retain and motivate qualified personnel
2. 55Our business and operations may be materially adversely affected in the event of information technology system failures or security breaches, and the costs and consequences of implementing data protection measures could be significant

Risks Related to Our Common Stock

1. 56such reverse stock split to be determined at the sole discretion of our Board of Directors, without further approval or authorization of our stockholders. However, there can be no assurances that we will be able to regain compliance with the Bid Price Rule
2. 57Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
3. 58require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws
4. 59The price of our common stock has been and may continue to be volatile and your investment in our stock could decline in value or fluctuate significantly, including as a result of analysts’ activities
5. 60the other risks and uncertainties described in this “Risk Factors” section
6. 61Securities or other litigation could result in substantial costs and may divert management’s time and attention from our business
7. 62We have broad discretion in the use of our cash, cash equivalents and investments and may not use them effectively
8. 63We are a “smaller reporting company”, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors
9. 64If we identify a material weakness in our internal control over financial reporting, it could have an adverse effect on our business and financial results and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our common stock
10. 65the future, or we experience high turnover of our personnel in our financial reporting functions, these shortcomings could have an adverse effect on our business and financial results, and the price of our common stock could be negatively affected
11. 66If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements, our projected guidance and/or our projected market opportunities prove inaccurate, our actual results may vary from those reflected in our projections and accruals
12. 67Our ability to use our net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be subject to certain limitations
13. 68Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition